Most likely
B+
Bull case
45%
Probability
Target price
$16.25
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
PSNL
PersonalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3B
Base case
40%
Probability
Target price
$15.25
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
15%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-14
Recent news sentiment (30D)
+72.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+54.1
Score
AI commentary
News tone is positive because of the Tempus acquisition, strong Q2 clinical growth, and expanded Medicare coverage, but confidence is moderated by low coverage and missing social, options, short-interest, and post-print analyst data. The queue labels an August 11 earnings date, while the available company/SEC earnings release is dated August 4; no separate August 11 company release or transcript is included. The memo therefore remains a cautious, deal-supported monitoring view rather than a high-conviction standalone valuation call.
RankAlpha Sentiment Codex - 2026-08-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-04eventQ2 clinical and reimbursement accelerationMedium impact
Q2 revenue rose 30% year over year to $22.4 million, clinical revenue rose 442% to $2.6 million, and clinical test volume rose 199% to 10,384. Medicare coverage expanded NeXT Personal to four indications. [#SEC-8K-2026-08-04] [#PR-EARNINGS-2026-08-04]
2026-11-12eventTempus acquisition spread resolutionHigh impact
Tempus agreed to acquire Personalis for stated consideration of $16.25 per share, implying roughly 12.7% upside from the $14.42 anchor price, subject to transaction-closing conditions and Tempus-stock exposure. [#SEC-8K-2026-07-20]
2027-08-14catalystMRD adoption and further reimbursement expansionHigh impact
More than 1,400 physicians were ordering NeXT Personal, while management cited ongoing evidence generation to support reimbursement expansion into additional indications. Execution remains the key uncertainty. [#PR-EARNINGS-2026-08-04]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-14 • Updated nightlySource: Internal modelMethodology